Molecular structure of Tranilast, CAS Number: 53902-12-8
Tranilast (CAS 53902-12-8)
See product citations (2)
Alternate Names:
2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propen-1-yl]amino]-benzoic acid
Application:
Tranilast is an inhibitor of angiogenesis and the release of histamine and prostaglandins
CAS Number:
53902-12-8
Purity:
≥98%
Molecular Weight:
327.33
Molecular Formula:
C18H17NO5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Tranilast is an angiogenesis inhibitor that also inhibits the release of histamine and prostaglandins from basophils and mast cells. Other functions of Tranilast include the ability to inhibit leukotrienes, oxygen radicals, cyclooxygenase-2 expression, cytokines, collagen synthesis, and blocks the production of IL-1 and IL-2 from human T-cells and macrophages. Studies indicate that Tranilast blocks vascular inflammation and disrupts the NF-kappaB/CBP interaction, which leads to the inhibition of NF-kappaB dependent transcription activation. Additionally, Tranilast has been reported to inhibit the release of PGE2 and TGF-beta from monocytes-macrophages and the transformation of fibroblasts to myofibroblasts, and contraction in vitro. Smooth muscle cell studies have revealed that Tranilast inhibits vascular smooth muscle cell growth, calcium entry, and acts as an antagonist of Angiotensin (angiotensin II).
Tranilast (CAS 53902-12-8) References
- Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53. | Takahashi, A., et al. 1999. Circ Res. 84: 543-50. PMID: 10082476
- [Determination of tranilast in human plasma by reversed-phase high performance liquid chromatography and its pharmacokinetics]. | Zhao, F., et al. 1998. Se Pu. 16: 78-9. PMID: 11324488
- Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells. | Spiecker, M., et al. 2002. Mol Pharmacol. 62: 856-63. PMID: 12237332
- Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. | Suzawa, H., et al. 1992. Jpn J Pharmacol. 60: 85-90. PMID: 1282575
- Tranilast: a novel weapon against insulin resistance. | Namazi, MR. and Soma, J. 2005. Med Hypotheses. 64: 1135-7. PMID: 15823702
- Activated macrophages as key mediators of capsule formation on adipose constructs in tissue engineering chamber models. | Zhan, W. and Lu, F. 2017. Cell Biol Int. 41: 354-360. PMID: 28102640
- Tranilast Treatment Attenuates Cerebral Ischemia-Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF-κB and PPARs. | Zhuo, Y. and Zhuo, J. 2019. Clin Transl Sci. 12: 196-202. PMID: 30548101
- Tranilast Directly Targets NLRP3 to Protect Melanocytes From Keratinocyte-Derived IL-1β Under Oxidative Stress. | Zhuang, T., et al. 2020. Front Cell Dev Biol. 8: 588. PMID: 32754591
- Tranilast attenuates neuropathic pain during type-2 diabetes by inhibiting hypoxia-induced pro-inflammatory cytokines in Zucker diabetic fatty rat model. | Zhang, W., et al. 2020. Arch Physiol Biochem. 1-14. PMID: 33307841
- Tranilast prevents doxorubicin-induced myocardial hypertrophy and angiotensin II synthesis in rats. | Zhan, C., et al. 2021. Life Sci. 267: 118984. PMID: 33383049
- Stromal nicotinamide N-methyltransferase orchestrates the crosstalk between fibroblasts and tumour cells in oral squamous cell carcinoma: evidence from patient-derived assembled organoids. | Zhao, H., et al. 2023. Oncogene.. PMID: 36823377
- Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. | Yamada, H., et al. 1994. J Biochem. 116: 892-7. PMID: 7533764
- Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. | Isaji, M., et al. 1997. Br J Pharmacol. 122: 1061-6. PMID: 9401770
Inhibitor of:
β ig-h3, Angiogenesis, Angiotensin, Asporin, COL11A1, COL13A1, COL15A1, COL16A1, COL19A1, COL1A2, COL21A1, COL22A1, COL28A1, COL29A1, COL3A1, COL4A1, COL5A3, COL6A, COL6A6, COL8A1, COL9A1, Collagen α2 Type VI, Collagen Type II, CRIM1, EG627094, eoxtaxin-3, FLRG, Fussel-18, GDF-11, GDF-9, GFAP, Hic-5, Human Thymic Fibroblasts, Inhibin β-E, Integrin β8, Laminin β-4, LEPREL2, LOC645781, LRRC32, Mast Cell Protease 10, Mast Cell Protease 7, Multimerin-2, Myofibroblasts, NALP1B, NALP4, NALP4E, NALP8, NOMO2, NPN, PCPE-2, Periostin, Podocan, PRELP, PRG-3, Procollagen Type III, PTGF-β, Reg lllγ, TGF beta, TGFβ2, TGFβ3, TGIF2LX1, TGIF2LX2, TIAF-1, TIMAP, TMEM100, Tryptase, Vasorin, VRL-1, WARP, YKL-39, and ZPLD1.Activator of:
β ig-h3, CD109, DAF-3, DAND5, DDR2, Epo, FAPα, fibrillin-3, Fibroblast Marker, GSDMDC1, Lefty-2, LTBP-1, Mast Cell Protease 10, Mast Cell Protease 2, Mast Cell Protease 8, Mast Cell Protease 9, MAWDBP1, SARA, Smad1, Smad2, Tβ-b, TARSH, TGF B3, TGFβ RIII, TGIF, TGIF2LX, TGIF2LY, TSC-22 D2, uPA, and ZNF512.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tranilast, 10 mg | sc-200389 | 10 mg | $31.00 | |||
Tranilast, 50 mg | sc-200389A | 50 mg | $103.00 | |||
Tranilast, 1 g | sc-200389B | 1 g | $283.00 | |||
Tranilast, 5 g | sc-200389C | 5 g | $978.00 |